(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

I-Mab (NASDAQ: IMAB) (the "Company”), a U.S.-based, global biotech company, focused on the development of precision ...

Research and development expenses for the fiscal year ended March 31, 2025 were $16.9 million compared with $24.4 million for the fiscal year ended March 31, 2024. The decrease of $7.5 million was ...

The neurogenesis rates of some olfactory sensory neuron subtypes are selectively accelerated in mice that are exposed to odors that stimulate those subtypes.

A protein found in our cells has emerged as a secret weapon against biological aging, acting like a glue to repair damaged ...